1Universidade de Caxias do Sul, Brazil
2Department of Gastroenterology and Hepatology, Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil
3Universidade de São Paulo, Brazil
*Corresponding author: Jonathan Soldera, Professor of Gastroenterology and Hepatology, Faculty of Medicine, Universidade de Caxias do Sul, Ver Mário Pezzi Av, 699/601, Caxias do Sul - RS, CEP 95084-180, Brazil
Submission: October 28, 2017; Published: December 15, 2017
ISSN 2637-7632Volume1 Issue2
Introduction: Hepatitis C has been treated with interferon and ribavirin for over a decade with described global sustained virological response rates of 33% to 56%. Direct acting antiviral drugs available since 2013 in USA and 2015 in Brazil are changing this reality.
Purpose: Analyze the real-life efficacy and safety of interferon-free therapy
Methods: Repot six cases of different treatments guided by north-american and european guildelines.
Results: Every reported patient achieved sustained virological response. The only adverse event was anemia in one patient.
Conclusion: Direct-acting antiviral drugs will dramatically change the population which can be treated and increase sustained virological response rates.
Keywords: Brazil; Chronic hepatitis C; Direct antiviral therapy; HCV; Real World